Esperion Therapeutics Posts Record Revenue Growth and Achieves Key Milestones in Q4 2025 Earnings Call.

Esperion Therapeutics reported record revenue growth in Q4 2025, with total revenue at $168.4 million, a 144% YoY increase. US net product revenue rose 38% YoY to $43.7 million, while collaboration revenue surged 232% YoY to $124.7 million. The company achieved a $55 million debt reduction and ended 2025 with $167.9 million in cash and cash equivalents. For 2026, Esperion projects operating expenses of $225-255 million, including non-cash stock compensation expenses.